Financial Report: Amgen

Amgen

3Q Revenues: $5.7 billion (+14%)

3Q Earnings: $1.9 billion (+50%)

YTD Revenues: $16.1 billion (+10%)

YTD Earnings: $5.1 billion (+33%)

Comments: Growth in the quarter was primarily driven by Enbrel (+30% to $1.5 billion), Sensipar (+29% to $353 million), Neulasta (+6% to $1.3 billion), Prolia (+25% to $320 million), XGEVA (+19% to $378 million ) and Kyprolis (+46% to $137 million). NEUPOGEN sales were down 5% to $284 million impacted by Sandoz’ filgrastim biosimilar in the U.S. R&D expenses were up 11% to $1.1 billion, driven by upfront payments related to the company’s recent deal activity and increased support for launch products, offset partially by savings from transformation and process improvement efforts.